Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Once-Weekly Basal Insulin Analogue in Type 1 Diabetes
An annual report is the one IND submission that looks back across the whole year and arrives on a fixed date, and it differs in purpose from protocol amendments, information amendments, and IND safety reports. This article prepares the regulatory operations components of an annual report for a hypothetical open IND for a once-weekly basal insulin analogue studied in adults with type 1 diabetes in a 52-week, open-label Phase 3 study against a once-daily basal insulin (412 of 600 planned participants entered). It tabulates enrollment by age, sex, and race, summarizes severe hypoglycemia as the main known risk, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13, completes Form FDA 1571 as an academic specimen, and builds a timeline that accounts for year-end holidays before a January 30, 2027 deadline. A comparison table shows how the annual report differs from the other three IND submissions.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle
Authors
- Peivand Pirouzi
- Happy Makvana
- Drashti Patel
- Sahil Patel
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24420511
- Primary Topic
- Healthcare Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00